IXICO Updates AI Neuroimaging Platform

Summary by AI ^BETAClose X

IXICO plc has released version 10 of its AI-driven neuroimaging platform, IXI™, which enhances data processing speed and volume, improves image reading precision, and integrates new tools for remote access and data quality. This latest generation of IXI™ supports IXICO's TechBio strategy by enabling external organizations to access the technology through licensing and partnering models, aiming to expand the company's addressable market and assist biopharmaceutical companies in making earlier, more informed decisions in drug development for neurological disorders.

Disclaimer*

IXICO plc

12 May 2026

IXICO plc

("IXICO", the "Company" or the "Group")

IXICO RELEASES LATEST VERSION OF AI-DRIVEN NEUROIMAGING TECHNOLOGY PLATFORM

IXI™ (Version 10) advances data processing speed and volume

12 May 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced the latest version release (v.10) of IXI™, IXICO's proprietary AI enabled neuroimaging platform that delivers clinical trial imaging and biomarker insights in neurological disease research.

The IXI™ 10.0 release brings advances in image reading precision and analysis, enables larger and faster image data processing, and integrates new tools for remote image access and data quality qualification. The latest generation of IXI™ lays the foundation for IXICO's technology to move beyond its traditional iCRO remit as part of the Group's TechBio strategy. The strategy is focused on increasing IXICO's addressable market by enabling external organisations to directly access IXICO's technology via licensing, technology integration and partnering models such as the recently announced collaboration with Medidata (26 March 2026).

About IXI™

Designed by neuroscience and data science experts, the IXI™ Platform is a proprietary suit of technologies and AI tools tailor-made for neurological disease complexity. IXI™ uses machine learning and deep learning to reliably process data from global trials and build algorithms that precisely measure key imaging biomarkers associated with the identification, progression and treatment of Alzheimer's, Parkinson's, Huntington's and other rare neurological diseases. It is the only technology platform of its kind specifically built for, and exclusively focussed on, neuroimaging processing and neurological biomarker analysis.

IXI™ is being used every day across the world. With over 30 cutting edge analytics algorithms the Platform integrates standardised high quality image data capture, image reading, advanced analysis and regulatorily compliant reporting of clinical data. IXI™ supports the biopharma industry to develop new medicines and diagnostic measures, informing decisions earlier in the drug development process via a single end to end platform.

Bram Goorden, Chief Executive Officer of IXICO, commented: "As the field of CNS is rapidly embracing precision medicine, the players in clinical development need technologies that deliver faster, more scalable and highly precise biomarker insights. The latest generation of our AI-driven technology platform IXI™ hosts some of the most advanced algorithms in neurodegenerative disease, increases accuracy and processing capacity and further strengthens data quality oversight, all while simplifying user interaction and integration in established partner platforms. This all with one objective in mind : helping biopharma make earlier and better-informed decisions."

Ends

For further information please contact:

IXICO plc	+44 (0) 20 3763 7499
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)	+44 (0) 20 7220 0500
Giles Balleny, Isaac Hooper (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales)

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotechs, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.

The IXI^TM Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END